NephCure Policy Priorities Provide the National Institutes of Health (NIH) with at least $46.1 billion in FY 2022. There are currently no FDA-approved drugs for FSGS, and scientists tell us that much more research needs to be done on the basic science behind FSGS and other Nephrotic Syndrome diseases. More research could lead to fewer patients reaching end-stage renal disease (ESRD) and tremendous savings in healthcare costs in the United States. NephCure works closely with the NIH, partnering with the agency on two large studies that will advance the pace of clinical research and support precision medicine. These studies, the Nephrotic Syndrome Study Network and the Cure Glomerulonephropathy Network, have already delivered significant data that have led to material benefits in FDA drug approval approaches. Our priority to provide funding to the NIH specifically includes: Providing a proportional increase for the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) and supporting FSGS/NS research opportunities. Cure Glomerulonephropathy (CureGN) is an important study with the goal of supporting precision medicine development for NS.Providing a proportional increase for the National Institute on Minority Health and Health Disparities (NIMHD) and supporting FSGS/NS research opportunities through grant and training programs. Supporting rare disease research at the National Center for Advancing Translational Sciences (NCATS). The NEPTUNE Study, part of the Rare Diseases Clinical Research Network, is a collaboration of the NIH, NephCure, and academic partners to pool resources and discover a cure. Provide $5 million for a Chronic Disease Education and Awareness Program at the Centers for Disease Control and Prevention (CDC). This program seeks to provide collaborative opportunities for chronic disease communities that lack dedicated funding from ongoing CDC activities. Such a mechanism allows public health experts at the CDC to review project proposals on an annual basis and direct resources to high impact efforts in a flexible fashion. Continue to include “Nephrotic Syndrome and Focal Segmental Glomerulosclerosis” as a condition eligible for study through the Department of Defense Peer-Reviewed Medical Research Program (PRMRP) for FY 2022. Nephrotic Syndrome (NS) is an umbrella term for the collection of signs and symptoms and related diseases that occur when the kidney filters leak protein into the urine. Focal Segmental Glomerulosclerosis (FSGS) is a disease that attacks the kidney’s filtering system (glomeruli), causing serious scarring. FSGS is one of the many causes of Nephrotic Syndrome, which occurs when valuable protein in the blood leaks into the urine (proteinuria). FSGS can cause end-stage renal disease (ESRD), at which point patients require dialysis or a kidney transplant. There is no cure or FDA-approved drug for FSGS, and it returns in approximately 30-40% of patients who receive kidney transplants.